Comprehensive structural glycomic characterization of the glycocalyxes of cells and tissues
»
Comprehensive structural glycomic characterization of the glycocalyxes of cells and tissues
The glycocalyx consists glycosylation of proteins and lipids and fcorms outermost layer of cells. It is involved in the process of inter- and intracellular fundamentals, including non-self cells and self-recognition, cell signaling, cell structure maintenance, and protective immunity. Characterization glycocalyx is therefore important to understand the physiology of the cell and elucidating its role in promoting health and disease. This protocol describes how to comprehensively characterize glycocalyx N-glycans and O-glycans of glycoproteins and glycolipids intact in parallel, using the same enriched membrane fraction.
Profile of glycans and glycolipids performed using nanoflow liquid chromatography-mass spectrometry (nanoLC-MS). Sample preparation, quantitative LC-tandem MS (LC-MS / MS) analysis, and data processing method is provided. In addition, we discuss the results of the analysis glycoproteomic that specific glycosylation of membrane proteins. To reduce the number of samples required, the N-glycan, O-glycan and glycolipid analysis performed on the same enriched fraction, whereas glycoproteomic analysis performed on a separate enriched fraction. Sample preparation process takes 2-3 d, while the time spent on instrumental analysis and data that can vary from 1 to 5 d for different sample sizes.
This workflow applies to both cell and tissue samples. systematic changes in the glycocalyx associated with certain glycoforms and glycoconjugates can be monitored by quantitation using this protocol. The ability to quantitate individual glycoforms and glycoconjugates will find utility in a variety of basic and applied clinical studies, including glycan-based biomarker discovery and therapy. congenital disorders of glycosylation (CDG) is caused by a defect in a gene that regulates various glycoconjugate biosynthesis. Some of the genes responsible have been identified in the process of N-glycosylation of proteins.
Analysis of mucin-type core-1 O-glycoforms of apolipoprotein C-III (apoCIII) has recently been revealed combined N- and O-glycosylation defects. We apply the matrix-assisted laser desorption / ionization mass spectrometry profile of glycoforms apoCIII 500 serum samples for screening CDG, and the reference values are determined.The contents apoCIII unglycosylated lower in early infancy, showed that the O-glycan occupancy should be judged based reference values of the same age.
Comprehensive structural glycomic characterization of the glycocalyxes of cells and tissues
An important function of glycans in Human Skin Model epithelium dissected by CRISPR-Cas9-Engineered Human Organotypic
glycome change characteristics during histogenesis and organogenesis, but our understanding of the importance of glycan structures selected for tissue formation and homeostasis incomplete.
Here, we present a human Organotypic platform that enables the genetic dissection of cellular glycosylation capacity and interrogation of the role of different types of glycans in tissue formation. We use CRISPR-Cas9 gene targeting to generate a 3D library of tissue selective skin Organotypic differ in their capacity to generate glycan structures on the main types of N- and O-linked glycoproteins and glycolipids.
Ibrutinib drug-Bovine Serum Albumin (BSA) Conjugate
Albumin (Human, Mouse, rat, bovine and others) removal kit (synthetic dye based matrix; sufficient to remove 20-40 mg BSA from Bioprocessed material), 2 ml aff column
Albumin (Human, Mouse, rat, bovine and others) removal kit (synthetic dye based matrix; sufficient to remove 50-100 mg BSA from Bioprocessed material), 5 ml aff column
Albumin (Human, Mouse, rat, bovine and others) removal kit (synthetic dye based matrix; sufficient to remove 250-500 mg BSA from Bioprocessed material), 25 ml aff column
Description: Untagged synthetic panspecies Galactose BSA Glycoconjugate for WB, ELISA. The biological activity of this protein has not yet been tested.
Glycated Bovine Serum Albumin (BSA) with ?-Galactose
Description: Untagged synthetic panspecies Galactose BSA Glycoconjugate for WB, ELISA. The biological activity of this protein has not yet been tested.
Glycated Bovine Serum Albumin (BSA) with ?-Galactose
Description: Untagged synthetic panspecies Galactose BSA Glycoconjugate for WB, ELISA. The biological activity of this protein has not yet been tested.
(DRAAGQPAG)3 peptide (repeat-sequence peptide of the P. vivax circumsporozoite protein, CSP) conjugated with BSA
Description: A competitive inhibition quantitative ELISA assay kit for detection of Bovine Serum Albumin (BSA) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.
Description: A competitive inhibition quantitative ELISA assay kit for detection of Bovine Serum Albumin (BSA) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.
Bovine serum albumin (BSA) removal kit (Antibody based aff matrix; sufficient to remove 1-2 mg BSA from Bioprocessed material), 2 ml aff column
Description: Lactacystin is a specific and an irreversible inhibitor of proteasome with IC50 value of 4.8 ?M [1].Lactacystin binds to the catalytic subunits of the 20 S proteasome and inhibits all the three peptidase activities of the proteasome, chymotrypsin-like, trypsin-like and caspase-like.
Description: Lactacystin is a specific and an irreversible inhibitor of proteasome with IC50 value of 4.8 ?M [1].Lactacystin binds to the catalytic subunits of the 20 S proteasome and inhibits all the three peptidase activities of the proteasome, chymotrypsin-like, trypsin-like and caspase-like.
Description: Lactacystin is a specific and an irreversible inhibitor of proteasome with IC50 value of 4.8 ?M [1].Lactacystin binds to the catalytic subunits of the 20 S proteasome and inhibits all the three peptidase activities of the proteasome, chymotrypsin-like, trypsin-like and caspase-like.
Description: Galactose Mutarotase (GALM) is a cytoplasmic enzyme that belongs to the Aldose Epimerase family. GALM is a Mutarotase that converts alpha-Aldose to the beta -Anomer. GALM is active on D-Glucose, L-Arabinose, D-Xylose, D-Galactose, Maltose and Lactose. GALM may be required for normal Galactose metabolism by maintaining the equilibrium of alpha- and beta - anomers of Galactose.
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound.
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound.
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound.
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound.
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound.
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound.
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound.
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound.
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human JWH-250, Synthetic Cannabinoid . This antibody is tested and proven to work in the following applications:
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human K2/spice, Synthetic Cannabinoids . This antibody is tested and proven to work in the following applications:
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human UR144/XLR11, Synthetic Cannabinoids . This antibody is tested and proven to work in the following applications:
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound.
This network library revealed different changes in skin formation associated with the loss of features for all glycoconjugates tested. Organotypic skin models provide phenotypic cues for different functions of glycoconjugates and serves as a unique resource for further genetic dissection and identification of certain structural features involved. This strategy also applies to other Organotypic network model.